Table 1 HBV patient characteristics and outcome of evaluation
N = 50 (100%) | |
|---|---|
Sex | |
Male | 22 (44%) |
Female | 28 (56%) |
Age (years) (mean ± SD) | 48 ± 9.7 |
Migrational background | |
Dutch / WE | 4 (8%) |
EE/EA | 12 (24%) |
NA | 2 (4%) |
SSA | 7 (14%) |
SEA | 23 (46%) |
LA | 2 (4%) |
ALT (U/l) (mean + SD) combined with HBV DNA levels (IU/mL) | |
Normal (0-34 U/l) and HBV DNA < 2.0 · 104 | 44 (88%) |
ALT >1xULN and HBV DNA < 2.0 · 104 | 3 (6%) |
ALT >1xULN and HBV DNA > 2,0 · 104 | 3 (6%) |
Fibrosis stage | |
Unknown | 2 (4%) |
F0-F1 | 45 (90%) |
F2-F3 | 3 (6%) |
Management advice | |
No Follow-up needed | 3 (6%) |
ALT levels every 6-12 months | 25 (50%) |
ALT levels and HCC screening every 6-12 months | 14 (28%) |
Strict follow-up every 3-6 months | 5 (10%) |
Antiviral therapy | 3 (6%) |